伊布替尼：套细胞淋巴瘤未来治疗的有力候选药物。 - Suppr

Suppr

超能文献

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

作者信息

Zhang Liang, Newberry Kate J, Wang Michael

出版信息

Expert Rev Clin Immunol. 2013 Jun;9(6):495-7. doi: 10.1586/eci.13.31.

DOI:10.1586/eci.13.31

PMID:23730878

Abstract

摘要

相似文献

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

Expert Rev Clin Immunol. 2013 Jun;9(6):495-7. doi: 10.1586/eci.13.31.

Ibrutinib approved for mantle cell lymphoma.

Cancer Discov. 2014 Jan;4(1):OF1. doi: 10.1158/2159-8290.CD-NB2013-172. Epub 2013 Dec 12.

Toward new treatments for mantle-cell lymphoma?

N Engl J Med. 2013 Aug 8;369(6):571-2. doi: 10.1056/NEJMe1307596.

Novel therapies for relapsed/refractory mantle cell lymphoma.

Best Pract Res Clin Haematol. 2018 Mar;31(1):105-113. doi: 10.1016/j.beha.2017.10.010. Epub 2017 Nov 20.

Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.

Hematol Oncol Clin North Am. 2020 Oct;34(5):903-921. doi: 10.1016/j.hoc.2020.06.007. Epub 2020 Aug 1.

Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.

Ann Hematol. 2017 Jun;96(6):1049-1050. doi: 10.1007/s00277-017-2964-3. Epub 2017 Feb 28.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23.

Ibrutinib for mantle cell lymphoma.

Future Oncol. 2016 Feb;12(4):477-91. doi: 10.2217/fon.15.342. Epub 2016 Jan 13.

[Ibrutinib prescription in B-cell lymphoid neoplasms].

Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25.

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

Expert Rev Clin Immunol. 2013 Jun;9(6):495-7. doi: 10.1586/eci.13.31.

Ibrutinib approved for mantle cell lymphoma.

Cancer Discov. 2014 Jan;4(1):OF1. doi: 10.1158/2159-8290.CD-NB2013-172. Epub 2013 Dec 12.

Toward new treatments for mantle-cell lymphoma?

N Engl J Med. 2013 Aug 8;369(6):571-2. doi: 10.1056/NEJMe1307596.

Novel therapies for relapsed/refractory mantle cell lymphoma.

Best Pract Res Clin Haematol. 2018 Mar;31(1):105-113. doi: 10.1016/j.beha.2017.10.010. Epub 2017 Nov 20.

Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.

Hematol Oncol Clin North Am. 2020 Oct;34(5):903-921. doi: 10.1016/j.hoc.2020.06.007. Epub 2020 Aug 1.

Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.

Ann Hematol. 2017 Jun;96(6):1049-1050. doi: 10.1007/s00277-017-2964-3. Epub 2017 Feb 28.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23.

Ibrutinib for mantle cell lymphoma.

Future Oncol. 2016 Feb;12(4):477-91. doi: 10.2217/fon.15.342. Epub 2016 Jan 13.

[Ibrutinib prescription in B-cell lymphoid neoplasms].

Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25.

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24.